Pier Maria Battezzati

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis

Pietro Invernizzi, Mauro Podda, Pier Maria Battezzati et al. · Journal of Hepatology · 2001 · 455 citations

Medicine, Immunology, Pathology +13

Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

Pietro Invernizzi, Andrea Crosignani, Pier Maria Battezzati et al. · Hepatology · 1997 · 293 citations

Medicine, Internal Medicine, Pathology +14

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

Maren H. Harms, Henk R. van Buuren, Christophe Corpechot et al. · Journal of Hepatology · 2019 · 277 citations · Full text

Medicine, Internal Medicine, Surgery +9

Frequency of monosomy X in women with primary biliary cirrhosis

Pietro Invernizzi, Monica Miozzo, Pier Maria Battezzati et al. · The Lancet · 2004 · 266 citations

Medicine, Genetics, Pathology +11